Trials / Completed
CompletedNCT04825678
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
Phase 4, Open-label Study to Evaluate Treatment Satisfaction With Erenumab in Patients With Migraine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erenumab | Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen). |
Timeline
- Start date
- 2021-06-11
- Primary completion
- 2023-09-28
- Completion
- 2023-09-28
- First posted
- 2021-04-01
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
42 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04825678. Inclusion in this directory is not an endorsement.